Status:

UNKNOWN

Stereotactic Body Radio Therapy (SBRT) for Early-stage Non Small Cell Lung Cancer (NSCLC)

Lead Sponsor:

Centre Leon Berard

Collaborating Sponsors:

The Biostatistics and Therapy Evaluation Unit

National Cancer Institute, France

Conditions:

Non Small Cell Lung Cancer

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this study is to evaluate local disease control after 2 years in patients with non-metastatic, non-operated non-small-cell lung cancer treated by radiotherapy. Eligible patients will b...

Detailed Description

The main objective of this study is to do a health economic evaluation of innovating techniques in radiotherapy. SBRT is the very precise delivery of high-powered radiation to small target volumes, u...

Eligibility Criteria

Inclusion

  • Non-operated non-small-cell lung cancer (NSCLC) (inoperable tumor or patient refusal of surgery)
  • cytologically or histologically proven NSCLC Or
  • primitive pulmonary tumor of unproven malignancy
  • macroscopically normal bronchial endoscopy, negative cytology and biopsies
  • AND size increase on 2 successive scans (at 10-12 weeks interval)
  • AND hypermetabolic PET-CT pattern
  • AND absence of other proven etiology
  • Tumor \< 5cm, distant (\> 1.5 cm) from large vessels, principally in the bronchus and spinal-cord
  • No metastasis: M0
  • No lymph node involvement: N0
  • Functional respiratory evaluation (FRE) compatible with thoracic irradiation
  • Maximum expiratory flow-volume \> 30% theoretical value
  • Age \>= 18
  • ECOG PS \<= 2
  • Female patients of childbearing potential: effective method of contraception
  • Written advice of the RCP (conciliation meeting) present in the patient file
  • Mandatory affiliation with a social security system
  • Written, signed informed consent

Exclusion

  • Previously operated tumors
  • Previous thoracic irradiation
  • Previous or concurrent primary malignancies at other sites (except basocellular skin cancer or cervical cancer in situ or complete remission for more than 5 years)
  • Life expectancy \< 6 months
  • Pregnant or lactating woman
  • Difficult follow-up
  • Patient deprived of freedom

Key Trial Info

Start Date :

April 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2013

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT00870116

Start Date

April 1 2009

End Date

March 1 2013

Last Update

March 6 2013

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

Centre Georges François Leclerc

Dijon, France, 21000

2

Centre Oscar Lambret

Lille, France, 59000

3

Centre Leon Berard

Lyon, France, 69008

4

Centre Val d'Aurelle Paul Lamarque

Montpellier, France, 34000